News

According to the deal, Hyglos will leverage Lonza’s patent-protected recombinant factor C technology in the production of endotoxin products. As part of the settlement, Lonza will cancel a

Jetrea, which is administered through a one-time, single intravitreal injection, breaks down the protein fibers which cause the abnormal traction between vitreous and macula that causes VMT. The

The new patent covers the method of retrieval, incubation and transplantation of cells derived from umbilical cord blood. The processed cells can be used to treat neurodegenerative diseases,

Certis CRT design-qualified shippers ensure ambient thermal protection for pharmaceuticals, biologics, vaccines and other high-value products, claims the company. Sonoco ThermoSafe vice president Russell Grissett said, "A regulatory

Premacure is currently developing a protein replacement therapy to treat retinopathy of prematurity (ROP), a rare and potentially blinding eye disorder that primarily affects premature infants. Based on

Fluvoxamine maleate ER capsules are indicated for the treatment of obsessive compulsive disorder (OCD), which is characterized by recurrent and persistent ideas or images that are recognized by

The Diana system protects clinicians from exposure to hazardous drugs and needlesticks, while protecting the patient preparation from exposure to environmental contaminants. The original version has been in

The contract will focus on the development and commercialization of Ligand’s Captisol-enabled, propylene glycol-free (PG-free) melphalan. According to the agreement, Ligand will earn license fee and is eligible

Under the agreement, the TSB and the Indian Global Innovation and Technology Alliance (GITA), sponsored by the Indian government, support the UK and Indian businesses and academics over